Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1681782rdf:typepubmed:Citationlld:pubmed
pubmed-article:1681782lifeskim:mentionsumls-concept:C0013023lld:lifeskim
pubmed-article:1681782lifeskim:mentionsumls-concept:C1415012lld:lifeskim
pubmed-article:1681782lifeskim:mentionsumls-concept:C0032743lld:lifeskim
pubmed-article:1681782pubmed:issue1lld:pubmed
pubmed-article:1681782pubmed:dateCreated1991-11-7lld:pubmed
pubmed-article:1681782pubmed:abstractTextThe syndrome of dopa-responsive dystonia comprises a minority of patients with dystonia, yet it is of considerable diagnostic importance because patients respond dramatically to L-dopa therapy. Benefits from this treatment are lasting, and the problems associated with long-term L-dopa therapy in patients with Parkinson's disease are generally absent. It has been suggested that this condition is due to a defect in the dopamine synthetic pathway, which is bypassed when patients are treated with L-dopa. We have studied [18F]dopa uptake in 6 patients with classic dopa-responsive dystonia (5 familial patients and 1 sporadic patient), aged 18 to 66 years. Data have been analyzed according to a graphic approach, calculating an influx constant for each region studied. We have also studied a seventh, clinically atypical, patient with juvenile dystonia-parkinsonism. Similar data have been calculated for a group of 10 healthy control subjects and 10 patients with Parkinson's disease. The 6 patients with typical dopa-responsive dystonia had a modest but significant reduction in the uptake of tracer into both caudate and putamen, which indicates a defect in the decarboxylation, vesicular uptake, and storage of [18F]dopa. This argues against the proposition that dopa-responsive dystonia is due to an inherited defect of tyrosine hydroxylase alone. In the atypical patient, however, we found a greater reduction of [18F]dopa uptake into both caudate and putamen, comparable with that in patients with Parkinson's disease.lld:pubmed
pubmed-article:1681782pubmed:languageenglld:pubmed
pubmed-article:1681782pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1681782pubmed:citationSubsetIMlld:pubmed
pubmed-article:1681782pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1681782pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1681782pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1681782pubmed:statusMEDLINElld:pubmed
pubmed-article:1681782pubmed:monthJullld:pubmed
pubmed-article:1681782pubmed:issn0364-5134lld:pubmed
pubmed-article:1681782pubmed:authorpubmed-author:MarsdenC DCDlld:pubmed
pubmed-article:1681782pubmed:authorpubmed-author:LeesA JAJlld:pubmed
pubmed-article:1681782pubmed:authorpubmed-author:LeendersK LKLlld:pubmed
pubmed-article:1681782pubmed:authorpubmed-author:FrackowiakR...lld:pubmed
pubmed-article:1681782pubmed:authorpubmed-author:HarwoodGGlld:pubmed
pubmed-article:1681782pubmed:authorpubmed-author:BrooksD JDJlld:pubmed
pubmed-article:1681782pubmed:authorpubmed-author:SawleG VGVlld:pubmed
pubmed-article:1681782pubmed:issnTypePrintlld:pubmed
pubmed-article:1681782pubmed:volume30lld:pubmed
pubmed-article:1681782pubmed:ownerNLMlld:pubmed
pubmed-article:1681782pubmed:authorsCompleteYlld:pubmed
pubmed-article:1681782pubmed:pagination24-30lld:pubmed
pubmed-article:1681782pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:meshHeadingpubmed-meshheading:1681782-...lld:pubmed
pubmed-article:1681782pubmed:year1991lld:pubmed
pubmed-article:1681782pubmed:articleTitleDopa-responsive dystonia: [18F]dopa positron emission tomography.lld:pubmed
pubmed-article:1681782pubmed:affiliationMRC Cyclotron Unit, Hammersmith Hospital, Villigen, Switzerland.lld:pubmed
pubmed-article:1681782pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1681782pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1681782pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:1681782pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1681782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1681782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1681782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1681782lld:pubmed